These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36826353)

  • 1. Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital.
    Pannier J; Nass N; Yaakoub MK; Stelzner FMM; Veit S; Kalomoiri M; Yassine M; Behre G
    Infect Dis Rep; 2023 Feb; 15(1):125-131. PubMed ID: 36826353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.
    Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F
    Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
    Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
    Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
    McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
    Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.
    Mazzotta V; Cozzi-Lepri A; Colavita F; Lanini S; Rosati S; Lalle E; Mastrorosa I; Cimaglia C; Vergori A; Bevilacqua N; Lapa D; Mariano A; Bettini A; Agrati C; Piselli P; Girardi E; Castilletti C; Garbuglia AR; Vaia F; Nicastri E; Antinori A
    Front Immunol; 2022; 13():868020. PubMed ID: 35514955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
    Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
    J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
    Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
    Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.
    Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J
    Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis.
    Tai YL; Lee MD; Chi H; Chiu NC; Lei WT; Weng SL; Liu LY; Chen CC; Huang SY; Huang YN; Lin CY
    PeerJ; 2023; 11():e15344. PubMed ID: 37180576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.